ARID1A and ovarian clear cell cancer: As our data indicated that the loss of ARID1A promotes the expression of interferon‐stimulated genes (ISGs), and limited accessibility and impaired expression of ISGs was found to correlate with poor immunotherapy response in ovarian clear cell carcinoma [21], we speculate that ARID1A‐negative tumors may be particularly sensitive to immunotherapy.